Lynn Seely (Myovant)
April 22, 2020 07:30 AM EDTUpdated 09:02 AM
R&D

First NDA in. Re­gion­al deal done. Now My­ovant has PhI­II da­ta to back up re­l­u­golix's push to an­oth­er block­buster mar­ket

Amber Tong

With two NDAs in prostate can­cer and uter­ine fi­broids lined up, My­ovant has tak­en the first step to­ward a third in­di­ca­tion for re­l­u­golix by un­veil­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

Re­cur­sion re­duces work­force; Ox­ford Nanopore teams up with UK Biobank

A service from the Financial Times